Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
Alpha Cognition Inc. (Nasdaq: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to ...
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch
Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and ...
Business Wire9d
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel ...
AOL7d
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition remains on track to launch Zunveyl in the United States in Q1 2025. The company will provide a corporate update and present its Launch Strategy on January 28, 2025.
Benzinga.com7d
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition licenses Zunveyl to China Medical System for $44M, covering Asia (excl. Japan), Australia, and New Zealand. ALPHA-1062 shows promise in reducing neuroinflammation and ...
Business Wire7d
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild ...
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing ...
Nasdaq7d
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and commercialization of Zunveyl in Asia, Australia and New Zealand.
Investing7d
Alpha Cognition licenses ZUNVEYL in Asia and Oceania
VANCOUVER, British Columbia - Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company currently valued at $2.49 million, and China Medical (TASE:PMCN) System Holdings Limited (CMS ...